Myriad Genetics Partners with SOPHiA GENETICS to Expand Prostate Cancer Biomarker Technology
Event summary
- Myriad Genetics and SOPHiA GENETICS are collaborating to advance the Prostate Genomic Instability Score (PrGIS) technology for precision oncology in prostate cancer.
- PrGIS is designed to assess chromosomal instability linked to homologous recombination deficiency (HRD) in prostate cancer patients.
- SOPHiA GENETICS will develop a decentralized companion diagnostic solution incorporating Myriad’s PrGIS technology, expanding access to over 1,000 connected institutions in 75 countries.
- Myriad plans to present PrGIS research co-authored with AstraZeneca at the ESMO Congress 2026.
The big picture
This collaboration underscores the growing emphasis on precision oncology and the need for actionable biomarkers in prostate cancer. By leveraging SOPHiA GENETICS’ global network, Myriad aims to address the geographic disparities in access to innovative therapies, a critical challenge in the biopharma industry. The partnership also highlights the strategic importance of companion diagnostics in accelerating the development of targeted cancer treatments.
What we're watching
- Clinical Validation
- How the upcoming ESMO Congress 2026 data will impact the validation and adoption of PrGIS as a prognostic and predictive biomarker in prostate cancer.
- Market Expansion
- The pace at which SOPHiA GENETICS can deploy the decentralized companion diagnostic solution globally, enhancing patient access to PrGIS.
- Commercialization Timing
- Whether Myriad can successfully expand the MyChoice CDx test for prostate cancer as a new indication and support biopharma partners in clinical trials.
Related topics